The influence of polymorphism in methotrexate pathway genes on efficacy and toxicity of methotrexate in patients with juvenile idiopathic arthritis

The influence of polymorphism in methotrexate pathway genes on efficacy and toxicity of methotrexate in patients with juvenile idiopathic arthritis - The influence of polymorphism in methotrexate pathway genes on efficacy and toxicity of methotrexate in patients with juvenile idiopathic arthritis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000002931

Enrollment

100

Registered

2009-12-23

Start date

2007-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Articular-type juvenile idiopathic arthritis (JIA)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients with juvenile idiopathic arthritis who were treated with MTX in our hospital and with prior written informed consent from patients and/or their parents.

Exclusion criteria

Exclusion criteria: The patient who was judged by physicians as an improper case for enrollment in this study

Design outcomes

Primary

Measure	Time frame
Efficacy and toxicity of methotrexate in patients with JIA	—

Secondary

Measure	Time frame
Subgroup analysis based on (1)time interval between onset and treatment, (2)response to therapy, (3)the level of anti-citrullinated peptide antibodies, and rheumatoid factor.	—

Countries

Japan

Outcome results